ERBB2 and ductal breast carcinoma in situ: Zhou [63] found out 186 Swedish patients of those classified as ductal carcinoma in situ (DCIS) were Luminal A (48.8%), 33 Luminal B/HER-2− (8.7%), 74 Luminal B/HER-2+ (17.4%), 61 HER-2+/ER− (16.0%) and 27 triple negative (7.1%).